- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00543556
MK0767 in Type 2 Diabetes (0767-012)
June 12, 2015 updated by: Merck Sharp & Dohme LLC
This is a clinical trial in patients with Type 2 Diabetes to test the safety of MK0767.
This study will also see how effective MK0767 is in lowering markers of glucose metabolism and improving the lipid profile and non-HDL cholesterol when compared with placebo and pioglitazone.
Study Overview
Study Type
Interventional
Enrollment (Actual)
514
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 2 Diabetes Mellitus patients between the ages of 21 and 75 inclusive
- Patient is willing to discontinue current therapy for the duration of the study
- Patient is not a heavy drinker
Exclusion Criteria:
- Patient has a history of Type 1 diabetes and/or ketoacidosis
- Patient has severe diabetic retinopathy, or nephropathy, or neuropath
- Patient has has anti-hyperglycemic therapy including insulin, or rosiglitazone and pioglitazone or 2 or more oral agents in combination within 8 weeks prior to visit 1
- Patient has a history of, allergy to, intolerance or hypersensitive to troglitazone, rosiglitazone, or pioglitazone including history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2001
Primary Completion (Actual)
November 1, 2003
Study Completion (Actual)
November 1, 2003
Study Registration Dates
First Submitted
October 5, 2007
First Submitted That Met QC Criteria
October 12, 2007
First Posted (Estimate)
October 15, 2007
Study Record Updates
Last Update Posted (Estimate)
June 15, 2015
Last Update Submitted That Met QC Criteria
June 12, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0767-012
- 2007_640
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
Clinical Trials on MK0767
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedDyslipidemia | Diabetes Mellitus, Type II
-
Merck Sharp & Dohme LLCTerminated
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedDiabetes Mellitus, Type 2
-
Merck Sharp & Dohme LLCTerminatedMetabolic X Syndrome Dyslipidemia